CAL
SMMT icon

Capital Advisors Ltd’s Summit Therapeutics SMMT Stock Holding History

Capital Advisors Ltd’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Buy
85
+84
+8,400% +$1.49K ﹤0.01% 1298
2026
Q1 		$0 Buy
+1
New +$16 ﹤0.01% 1583

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Capital Advisors Ltd's SMMT Position: Q2 2026 in Review

Capital Advisors Ltd increased its Summit Therapeutics (SMMT) stake by 8,400% in Q2 2026, buying an estimated $1.49K and bringing the position to 85 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1298.

Capital Advisors Ltd first reported a position in SMMT in Q1 2026 and has held it in 2 quarters since. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Capital Advisors Ltd held 85 shares of Summit Therapeutics worth $1K as of Q2 2026.
  • Capital Advisors Ltd bought 84 Summit Therapeutics shares in Q2 2026, an estimated $1.49K.
  • Summit Therapeutics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #1298 holding.
  • Capital Advisors Ltd first reported a position in Summit Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.